XML 78 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Significant accounting policies - Additional Information (Detail) - AUD ($)
 1 Months Ended 12 Months Ended
Apr. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Disclosure of summary of significant accounting policies [line items]          
Consolidated loss after income tax   $ 8,421,960 $ 12,467,466 $ 10,270,000  
Net current asset position   21,064,264 5,586,128    
Net cash outflows from operating activities   9,111,000 8,810,000 6,714,000  
Consolidated cash in hand and at bank   27,586,760 $ 8,764,044 $ 5,434,000 $ 5,956,000
Clinical Trials [Member] | Covid Ninteen [Member]          
Disclosure of summary of significant accounting policies [line items]          
Proceeds from funding for project purpose $ 9,000,000 $ 25,000,000      
Research and development tax incentive program [member]          
Disclosure of summary of significant accounting policies [line items]          
Additional tax deduction percentage   43.50%      
Top of range [member] | Research and development tax incentive program [member]          
Disclosure of summary of significant accounting policies [line items]          
Earning income   $ 20,000,000      
Licensing agreement for paxalisib [member]          
Disclosure of summary of significant accounting policies [line items]          
Remaining useful life,licensing agreement   15 years      
Licensing agreement for EVT801 [member]          
Disclosure of summary of significant accounting policies [line items]          
Remaining useful life,licensing agreement   12.5 years